专注化学 创新未来 药石科技2022年度 & 2023年一季度业绩交流 2023年4月23日 www.pharmablock.com product.pharmablock.com 本次业绩交流会的相关信息、材料的所有知识产权及权利均属于南京药石科技股份有限公司（"药石科技"或"公 司"）所有，任何人未经药石科技事先许可，不得对会议进行录音、录像或以任何形式对外传播会议相关材料。本 次会议并非意图提供相关事项的完整表述，有关信息请以公司在深圳证券交易所网（www.szse.cn）和公司指定媒体 刊登的2022年年度报告及2023年第一季度报告为准。 2 公司战略 § 通过化学和技术创新，提升产品和服务在质量、EHS合规、成本和速度上的竞争力 药物发现 临床前 临床I-III期 商业化 创新技术中心（TIC） (连续流技术、微填充床技术、金属催化、生物催化、设备工程) 小分子 PROTAC ADC 寡核苷酸 肽类 1. DELT/FBDD/AIDD库 2. H2L and LO to PCC服务 注册起始物料/中间体/原料药/制剂 (工艺化学、技术转移和生产、固态化学、质量分析、注册申报) 药物发现的分子砌块 ...

Financial Performance - The company's revenue for 2022 was ¥1,594,699,978.41, representing a 32.71% increase compared to ¥1,201,629,070.94 in 2021[23]. - Net profit attributable to shareholders decreased by 35.42% to ¥314,223,824.02 in 2022 from ¥486,559,403.95 in 2021[23]. - The net profit after deducting non-recurring gains and losses increased by 14.15% to ¥265,972,288.46 in 2022[23]. - The total assets at the end of 2022 were ¥4,862,189,119.46, a 38.65% increase from ¥3,506,922,491.19 at the end of 2021[23]. - The net assets attributable to shareholders increased by 9.48% to ¥2,657,635,982.95 at the end of 2022[23]. - The basic earnings per share decreased by 35.77% to ¥1.58 in 2022 from ¥2.46 in 2021[23]. - The cash flow from operating activities was ¥246,608,762.55, a 3.60% increase from ¥238,029,950.44 in 2021[23]. - The company reported a weighted average return on equity of 12.44% in 2022, down from 22.61% in 2021[23]. - The quarterly revenue for Q4 2022 was ¥409,997,868.92, showing a slight decrease from Q3 2022[26]. - In 2022, the company reported a total non-operating income of approximately $48.25 million, a significant decrease from $253.56 million in 2021[30]. Business Operations - The company operates in the global drug research and development sector, focusing on innovative chemical products and services, including drug molecular building blocks and CDMO services[3]. - The company’s main business includes the development, production, and sales of drug intermediates and active pharmaceutical ingredients[3]. - The company has a comprehensive drug discovery technology platform and offers technology transfer services based on drug molecular building blocks[3]. - The company has a focus on expanding its market presence and enhancing its research capabilities in drug development[3]. - The company has established partnerships with nearly all of the top 20 global pharmaceutical companies and hundreds of small to medium-sized biotech firms[43]. - The company has a project pipeline with 1,750 projects in preclinical to Phase II and 60 projects in Phase III to commercialization, indicating sustainable growth[64]. Research and Development - The company has developed a diverse library of molecular building blocks, enabling rapid design and synthesis for drug discovery, significantly reducing R&D costs and timelines[40]. - The company’s R&D expenses amounted to 168 million yuan, an increase of 54 million yuan or 47.62% year-on-year, with an R&D expense ratio of 10.56%[59]. - The company has applied for 28 new patents and obtained 17 new patents during the reporting period, totaling 122 valid patents by the end of the period[55]. - The company has developed a unique AI drug discovery platform that generates molecules with superior drug-likeness, significantly reducing computational requirements[73]. - The company achieved breakthroughs in structural biology services, enhancing its capabilities in early-stage compound discovery across various disease areas[74]. Market Trends and Challenges - The company faces potential risks including a decline in drug research market demand, changes in industry policies, intensified market competition, and quality control risks[3]. - The success rate of clinical development across all therapeutic areas dropped to 6.3% in 2022, indicating increased challenges in drug development[37]. - The Chinese CDMO market is projected to grow at a compound annual growth rate (CAGR) of approximately 20% over the next five years, double the global growth rate[38]. - Emerging biotech companies contributed to 72% of the clinical development pipeline, highlighting a shift in innovation dynamics within the pharmaceutical industry[36]. Corporate Governance - The company has a comprehensive governance structure in place, ensuring effective checks and balances among its decision-making bodies[149]. - The company maintains a complete and independent operational capability, with clear separation from its controlling shareholders in terms of assets, personnel, and business operations[150]. - The company has established an independent financial department with specialized personnel, ensuring financial operations are independent from controlling shareholders and their other enterprises[152]. - The company has a structured governance framework, including a shareholder meeting, board of directors, supervisory board, and management team, ensuring independent operational management[153]. - The company has not faced any penalties from securities regulatory agencies in the past three years for its current and former directors and supervisors[171]. Employee and Talent Management - The company has attracted over 1,000 graduates from renowned universities in recent years, enhancing its talent pool[57]. - The company has implemented a stock incentive plan, granting 981,100 restricted shares to 206 mid-to-senior level employees to enhance employee motivation and retention[94]. - The company has a total of 12 directors and supervisors, with the highest individual remuneration being RMB 234,000 for the general manager[176]. - The company has a total of 2,487 employees, with 1,508 technical personnel, representing approximately 60.5% of the total workforce[186]. - The company has established a dual career development path for employees, focusing on both professional and managerial growth[188]. Environmental and Social Responsibility - The company is committed to promoting green pharmaceutical manufacturing and exploring innovative low-carbon technologies[139]. - The company has increased investment in environmental protection facilities and improved management levels to ensure safety in production and environmental protection[142]. - The company has not experienced any major safety or environmental incidents since its establishment, despite increasing pressure from expanding business operations[142]. Financial Management and Fundraising - The company successfully issued convertible bonds, resulting in an increase in payable bonds to ¥1,045,631,907.14, which accounted for 21.51% of total liabilities[114]. - The company raised a total of RMB 1,143,301,603.77 through the issuance of convertible bonds in 2022, with actual usage amounting to RMB 1,127,545,752.36[128]. - The company has a remaining unused raised fund amount of CNY 45,496,090[126]. - The company reported a fair value change gain of CNY 3,352,426.59 as of December 31, 2022[122]. - The company has a structured remuneration decision-making process involving the compensation and assessment committee[172]. Dividend Policy - The company reported a cash dividend of RMB 1.00 per 10 shares, totaling RMB 19,966,421.70, which represents 100% of the total distributable profit[192]. - The company has established a cash dividend policy that requires a minimum of 20% of profits to be distributed as cash dividends during growth phases with significant capital expenditures[192]. - The company’s cash dividend distribution was completed by June 13, 2022, following the shareholder meeting on April 4, 2022[190].

Financial Performance - The company's revenue for Q1 2023 was CNY 383,440,937.44, representing a 14.24% increase compared to CNY 335,643,580.55 in the same period last year[6] - Net profit attributable to shareholders decreased by 18.47% to CNY 57,755,969.84 from CNY 70,839,845.23 year-on-year[6] - The basic earnings per share fell by 19.44% to CNY 0.29 from CNY 0.36 in the same period last year[6] - Net profit for Q1 2023 was ¥57,755,961.44, a decrease of 22.3% from ¥74,367,424.72 in Q1 2022[24] - The total comprehensive income attributable to the parent company was CNY 56,506,003.88, a decrease from CNY 70,600,622.80 in the previous period, representing a decline of approximately 19.99%[25] Cash Flow - The net cash flow from operating activities surged by 277.85% to CNY 75,015,353.97, up from CNY 19,853,090.75 in the previous year[6] - The net cash flow from operating activities was CNY 75,015,353.97, significantly up from CNY 19,853,090.75 in the previous period, indicating an increase of approximately 276.56%[28] - The total cash inflow from investment activities was CNY 119,249,255.06, down from CNY 771,161,653.00 in the previous period, reflecting a decrease of about 84.54%[28] - The net cash flow from financing activities was CNY 160,009,193.27, compared to CNY 152,081,619.07 in the previous period, showing an increase of approximately 5.87%[28] - The total cash and cash equivalents at the end of the period were CNY 820,190,549.66, compared to CNY 691,525,233.54 at the end of the previous period, an increase of approximately 18.61%[28] Assets and Liabilities - The company's total assets grew by 2.93% to CNY 5,004,414,338.77 from CNY 4,862,189,119.46 at the end of the previous year[6] - Current liabilities totaled ¥757,364,339.56, a slight increase from ¥739,178,415.06 in the previous year[22] - Long-term borrowings increased to ¥396,740,667.16, compared to ¥346,740,667.16 in Q1 2022, reflecting a growth of 14.4%[22] - The equity attributable to shareholders of the parent company rose to ¥2,721,037,027.73, compared to ¥2,657,635,982.95 in the previous year[22] Research and Development - Research and development expenses increased by 75.81% to CNY 48,393,224.73, compared to CNY 27,526,324.50 in the same period last year[10] - Research and development expenses rose to ¥48,393,224.73, a significant increase of 75.7% compared to ¥27,526,324.50 in the same period last year[24] Revenue Segments - The CDMO segment contributed ¥294,454,899.25, accounting for 76.79% of total revenue, with a year-on-year growth of 15.50%[18] - The company’s revenue from molecular building blocks was ¥87,016,896.24, which is 22.69% of total revenue, showing an 11.55% increase year-on-year[18] - The company’s other revenue segment saw a decline of 26.89% year-on-year, totaling ¥1,969,141.95[18] Shareholder Information - The top shareholder, Yang Minmin, holds 20.69% of the shares, with 30,980,264 shares pledged[16] - The total number of common stock shareholders at the end of the reporting period was 28,597[13] - The total number of restricted shares at the end of the period was 31,211,339, with no new restrictions added during the period[16] Operational Metrics - The company reported a gross profit margin of approximately 45.5% for Q1 2023, down from 52.2% in Q1 2022[24] - Total operating costs increased to ¥344,985,836.29, up 35.5% from ¥254,700,510.42 in the previous year[23] - The company reported a significant increase in cash received from tax refunds, which rose by 78.48% to CNY 29,222,569.06 from CNY 16,372,641.23 year-on-year[10] - The company experienced a decrease in cash flow from investment activities, with cash recovered from investments dropping by 85.46% to CNY 111,529,536.99 from CNY 767,284,122.10 in the previous year[11] - The company did not conduct any mergers or acquisitions during the reporting period, with no net profit reported from merged entities[25]

南京药石科技股份有限公司（以下简称"公司"）定于2023年5月5日（星期 五）15:00至17:00在全景网举办2022年度业绩网上说明会，本次年度业绩说明会 将采用网络远程的方式举行，投资者可登录全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 | 证券代码：300725 | 证券简称：药石科技 | 公告编号：2023-042 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 （问题征集专题页面二维码） 特此公告。 南京药石科技股份有限公司董事会 2023年4月22日 出席本次业绩说明会的人员有：公司董事长杨民民先生、财务总监兼董事会 秘书吴奕斐女士、独立董事WEIZHENG XU先生、保荐代表人唐澍女士。 为充分尊重投资者，进一步提升本次业绩说明会的交流效果及针对性，现就 公司2022年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意 ...

专注化学，创新医药 | --- | --- | --- | |---------------------------------------------|-------|------------------| | | | | | | | | | 药石科技 2020 2020 年9月2日 | | 年中期业绩交流会 | | | | | | | | | | www.pharmablock.com product.pharmablock.com | | | | | | | Confidential 保密 01 P A R T业务持续增长 cninf 空 www.cninf.com.cn Confidential 保密 财务数据 PharmaBlock 营业收入 归属于上市公司 股东的净利润 8734万元 同比增长 58.17% 同比增长 26.08% 同比增长 25.41% 同比增长 388.81% 基本每股收益 0.6元/股 同比增长 25.00% 加权平均 净资产收益率 11.05% 同比增长 0.10% 总资产 13.13亿元 同比增长 27.63% 归属于上市公司 股东的净资产 8.29亿元 同比增长 11. ...

Group 1: Company Performance - The company experienced a significant growth in Q2 2020 compared to Q1, attributed to the recovery from the pandemic and improved production efficiency, with capacity utilization reaching new levels [1] - The net cash flow increased by 388% in the first half of 2020 due to favorable collection conditions [2] - The company's gross profit margin and net profit margin decreased, primarily due to stock incentive expenses of approximately 22.25 million yuan, but remained stable when excluding this impact [3] Group 2: Market and Industry Insights - The pandemic has had a substantial impact on the industry, with ongoing uncertainties in international political situations affecting the return of API raw materials and drug products [1] - The company plans to mitigate international influences by expanding domestic markets and optimizing the layout of overseas R&D and production bases [2] - The pricing for PCC molecules varies significantly based on target and market, with domestic old targets priced around 20-30 million yuan and new targets ranging from 50 million to 100 million yuan [3] Group 3: Strategic Developments - The company is focusing on enhancing team capabilities, optimizing management systems, and keeping abreast of industry trends [4] - The company does not have significant customer dependency, indicating a healthy distribution of overall orders [4] - The company is exploring potential collaborations with pharmaceutical companies, leveraging its early involvement in drug discovery [4]

证券代码：300725 证券简称：药石科技 南京药石科技股份有限公司投资者关系活动记录表 编号：2019-002 | --- | --- | --- | --- | |-----------------------|---------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------| | 投资者关系活 \n动类别 | ■特定对象调研 □分析师会议 \n■现场参观 □其他 | ■媒体采访 \n□业绩说明会 □新闻发布会 □路演活动 \n（请文字说明其他活动内容） | | | | 深交所投教中心 刘俊余 | | | | | 证券时报 | 臧晓松 | | | 参与单位名称 | | 全景网 刘民江、张原、陈昊 | | | 及人员姓名 | 华泰证券 刘佳奇 | 等中小投资者 | | | | 南京证券 潘兰兰 ...

证券代码：300725 证券简称：药石科技 南京药石科技股份有限公司投资者关系活动记录表 编号：2019-001 | --- | --- | --- | --- | |--------------|--------------------------|---------|--------------------------------------------------| | 投资者关系活 | ■ | | 特定对象调研 □分析师会议 □媒体采访 | | | | | □业绩说明会 □新闻发布会 □路演活动 | | 动类别 | □ | | 现场参观 □其他 （请文字说明其他活动内容） | | | | | 国金证券 王班 交银施罗德 张胤 | | 参与单位名称 | | | 东吴证券 全铭 太平保险 姚宏福 | | | | | 东吴证券 焦德智 英大保险 王喆 | | 及人员姓名 | | | 银华基金 魏卓 中英人寿 朱睿 | | | 长城基金 龙宇飞 | | | | 时间 | 2019 年 7 月 | 16 日 | | | 地点 | 江苏省南京市高新区中丹园 | | B 座 15 楼 | | 上市公司接待 | 董事 ...

证券代码：300725 证券简称：药石科技 南京药石科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |--------------|-------|-------|-----------------------------------------------| | | | | | | | | | 编号： 2018-001 | | | ■ | | 特定对象调研 □分析师会议 □媒体采访 | | 投资者关系活 | □ | | 业绩说明会 □新闻发布会 □路演活动 | | 动类别 | □ | | 现场参观 □其他 （请文字说明其他活动内容） | | 参与单位名称 | | | 中信建投 袁清慧 兴业证券 孙媛媛 | | 及人员姓名 | | | 华泰证券 李沄、郭梁良 平安医药 倪亦道、邱晓旭 | | | | | 东兴证券 胡偌碧 中金公司 谭宸航、陈曦、帅为 | | | | | 华创证券 李民蔚、孙渊 国联证券 周静、邓国凤 | | | | | 国海证券 周超泽 南京证券 时松 | | | | | 广发证券 姚凯飞 华金证券 李伟 | | | | | 招商证券 李勇剑 东方财 ...

南京药石科技股份有限公司投资者关系活动记录表 编号：2022-01 证券代码：300725 证券简称：药石科技 | --- | --- | --- | --- | |--------------|------------------------------|--------------------------------------|--------------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | □媒体采访 | | 投资者关系活 | □ 业绩说明会 | | □新闻发布会 □路演活动 | | 动类别 | □现场参观 | □ | 其他（电话会议） | | 参与单位名称 | | | 国盛证券、上投摩根基金、民生加银基金、富安达基金等机构共 26 名 | | 及人员姓名 | 参与人员 | | | | 时间 2022 | 年 2 月 24 日 | | | | 地点 | 公司会议室 | | | | 上市公司接待 | 总经理 | 苗文芳 | 博士 | | 人员 | 财务总监 吴奕斐 | | | | | ...